Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

9.210 +0.550 (+6.35%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 275,466
Open 8.550
Bid (Size) 9.100 (1)
Ask (Size) 9.250 (1)
Prev. Close 8.660
Today's Range 8.550 - 9.300
52wk Range 4.530 - 22.49
Shares Outstanding 13,054,018
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analysis of Medical Records Repeatedly Links Viruses to Alzheimer’s
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025
Via Investor Brand Network
Exposures Product Safety

Performance

YTD
-51.35%
-51.35%
1 Month
+5.38%
+5.38%
3 Month
-19.14%
-19.14%
6 Month
-6.50%
-6.50%
1 Year
+19.15%
+19.15%

More News

Read More
Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Addressing Vision Problems Could Lower Risk of Dementia, Study Finds
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Expert Says Alzheimer’s Disease Could Be an Autoimmune Illness
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast
Via Investor Brand Network
ANVS Stock Earnings: Annovis Bio Beats EPS for Q2 2024
Via InvestorPlace
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton
Via Investor Brand Network
Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.